Vandana Singh

Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales guidance to $3.6 billion–$3.8 billion.

Private equity firms, including Blackstone, are exploring bids for UnitedHealth's UK Optum unit just two years after the EMIS acquisition.

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and financial guidance.

Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission.

Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but reporting cases of drug-induced liver injury.

Praxis stock jumps after Phase 3 trials show ulixacaltamide significantly improves essential tremor symptoms and meets key efficacy endpoints.

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Abbott eyes 10% EPS growth in 2026 with CGM momentum, new nutrition contracts, and medical device launches driving global expansion.

FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by March 2026.

Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some participants.